Incyte Corporation (INCY)
| Market Cap | 13.96B |
| Revenue (ttm) | 4.24B |
| Net Income (ttm) | 32.62M |
| Shares Out | 193.52M |
| EPS (ttm) | 0.15 |
| PE Ratio | 427.87 |
| Forward PE | 12.56 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,287,509 |
| Open | 71.66 |
| Previous Close | 71.38 |
| Day's Range | 71.50 - 72.97 |
| 52-Week Range | 50.35 - 83.95 |
| Beta | 0.70 |
| Analysts | Buy |
| Price Target | 74.76 (+3.68%) |
| Earnings Date | Feb 10, 2025 |
About INCY
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhib... [Read more]
Financial Performance
In 2024, Incyte's revenue was $4.24 billion, an increase of 14.76% compared to the previous year's $3.70 billion. Earnings were $32.62 million, a decrease of -94.54%.
Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for INCY stock is "Buy." The 12-month stock price forecast is $74.76, which is an increase of 3.68% from the latest price.
News
Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration
WILMINGTON, Del. & BURLINGAME, Calif.--(BUSINESS WIRE)--Incyte and Genesis Therapeutics announce strategic AI-focused research collaboration.
Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of March: Cowen 45th Annual Health Care Conference o...
Reevaluating Incyte Corporation After Earnings (Technical Analysis)
Incyte's recent earnings call disappointed the market, causing a 10.52% drop, but management's bullish comments and no debt position suggest a promising future. Technically, INCY is currently below it...
Incyte: Q4 Earnings Outlines Multiple Drug Launches In 2025
Incyte's Q4 2024 earnings showed mixed results with slight revenue beat but missed non-GAAP earnings estimates. The stock has declined due to 2025 guidance coming below expectations. Despite slowing ...
Incyte Corporation (INCY) Q4 2024 Earnings Call Transcript
Incyte Corporation (NASDAQ:INCY) Q4 2025 Earnings Conference Call February 10, 2025 8:00 AM ET Company Participants Ben Strain - Associate Vice President, Investor Relations Herve Hoppenot - Chief Ex...
Incyte reports quarterly sales above estimates on strong demand for key drugs
Drugmaker Incyte Corp reported fourth-quarter revenue above Wall Street estimates on Monday, boosted by strong demand for its key blood-cancer drug Jakafi and skin-disorder treatment Opzelura.
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones.
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Incyte to Report Fourth Quarter and Year-End 2024 Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2024 financial results conference call and webcast for 8:00 a.m. ET on Mon...
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes
– U.S. launch expected in early February – – Niktimvo is the first and only approved treatment for chronic GVHD that targets CSF-1R to reduce the drivers of inflammation and fibrosis – – Pivotal data ...
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...
Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference.
Incyte: Multiple Drug Launches Bode Well For Future Growth
Incyte's robust growth, led by JAKAFI and OPZELURA, is set to increase with new product launches of MONJUVI, ZYNZY, and NIKTIMVO in 2025. Analysts expect Incyte's revenues to grow by ~10% annually unt...
Incyte to Present at Upcoming Investor Conference
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) announced today that it will present at the 43rd Annual J. P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 am (PST). The p...
Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH24--Late-Breaking Tafasitamab (Monjuvi®) Data Demonstrate Significantly Improved Progression-Free Survival in Relapsed or Refractory Follicular Lymphoma...
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz) in Combination with Platinum-Based Chemotherapy in NSCLC.
Incyte Announces Updated Presentation Time for Upcoming Investor Conference
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will now present at Citi's 2024 Global Healthcare Conference on Tuesday, December 3, 2024 at 8:00 a.m. The presentation ...
Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH24--Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting.
Incyte Stock Slumps After Firm Scraps Drug, Pauses Enrollment in Other Study
Incyte (INCY) led S&P 500 decliners Tuesday afternoon after the pharmaceutical firm said it will stop developing one drug and pause enrollment in the study of another.
Incyte Is the S&P 500's Worst Performer Today. What's Hitting the Stock.
The biopharmaceutical company provided disappointing updates on two research studies.
Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges
On Monday, Incyte Corporation INCY announced that it will pause enrollment in the ongoing Phase 2 study of MRGPRX2 (INCB000262) in chronic spontaneous urticaria (CSU).
Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs.
Incyte: Q3 Earnings Ramping Up Growth To Jump The Patent Cliff
Incyte reported strong Q3 revenue growth, mainly driven by Jakafi and Opzelura, with a 24% increase year-over-year. New product approvals, like Niktimvo, should diversify Incyte's revenue and reduce r...
Incyte's Jakafi Demand Is Strong, Analyst Upgrades Stock
On Tuesday, Incyte Corporation INCY reported third-quarter revenue of $1.14 billion, up 24% year over year, beating the consensus of $1.08 billion.
Incyte Corporation (INCY) Q3 2024 Earnings Call Transcript
Incyte Corporation (NASDAQ:INCY) Q3 2024 Results Conference Call October 29, 2024 8:00 AM ET Company Participants Ben Strain - Associate Vice President, Investor Relations Herve Hoppenot - Chief Exec...